Case Report: Response to ipilimumab and nivolumab in a patient with adrenocortical carcinoma
BackgroundAdrenocortical carcinoma (ACC) is a rare malignancy with limited treatment options. The evidence for the use of immunotherapy in ACC has been conflicting, with overall response rates ranging from 6 – 33%.Case presentationWe describe the case of a 32 year old patient who was initially thoug...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1242560/full |
| _version_ | 1827821646562459648 |
|---|---|
| author | Rebecca Charles Divine Madhu Alexander Powles Adam Boyde Owen Hughes Nagappan Kumar Sing Yu Moorcraft |
| author_facet | Rebecca Charles Divine Madhu Alexander Powles Adam Boyde Owen Hughes Nagappan Kumar Sing Yu Moorcraft |
| author_sort | Rebecca Charles |
| collection | DOAJ |
| description | BackgroundAdrenocortical carcinoma (ACC) is a rare malignancy with limited treatment options. The evidence for the use of immunotherapy in ACC has been conflicting, with overall response rates ranging from 6 – 33%.Case presentationWe describe the case of a 32 year old patient who was initially thought to have an inoperable clear cell renal cell carcinoma and was treated with immunotherapy with ipilimumab and nivolumab. The patient had an excellent partial response to treatment. Further work-up prior to consideration of surgery demonstrated that the tumour was an ACC, rather than a renal cancer. She had a right adrenalectomy and right hepatectomy, achieving an R0 resection and remains disease-free one year after surgery.ConclusionThis case illustrates the challenge of diagnosing ACC, and that doublet immunotherapy with ipilimumab and nivolumab can have significant clinical efficacy in ACC. |
| first_indexed | 2024-03-12T01:47:17Z |
| format | Article |
| id | doaj.art-48dbd7f336e54f678ff43fe0fa749034 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-12T01:47:17Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-48dbd7f336e54f678ff43fe0fa7490342023-09-08T20:44:55ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-09-011310.3389/fonc.2023.12425601242560Case Report: Response to ipilimumab and nivolumab in a patient with adrenocortical carcinomaRebecca Charles0Divine Madhu1Alexander Powles2Adam Boyde3Owen Hughes4Nagappan Kumar5Sing Yu Moorcraft6Pathology Department, University Hospital of Wales, Cardiff, United KingdomSchool of Medicine, Cardiff University, Cardiff, United KingdomRadiology Department, Swansea Bay University Health Board, Swansea, United KingdomPathology Department, University Hospital of Wales, Cardiff, United KingdomDepartment of Urology, University Hospital of Wales, Cardiff, United KingdomCardiff Liver Unit, University Hospital of Wales, Cardiff, United KingdomOncology Department, South West Wales Cancer Centre and Swansea University Medical School, Swansea, United KingdomBackgroundAdrenocortical carcinoma (ACC) is a rare malignancy with limited treatment options. The evidence for the use of immunotherapy in ACC has been conflicting, with overall response rates ranging from 6 – 33%.Case presentationWe describe the case of a 32 year old patient who was initially thought to have an inoperable clear cell renal cell carcinoma and was treated with immunotherapy with ipilimumab and nivolumab. The patient had an excellent partial response to treatment. Further work-up prior to consideration of surgery demonstrated that the tumour was an ACC, rather than a renal cancer. She had a right adrenalectomy and right hepatectomy, achieving an R0 resection and remains disease-free one year after surgery.ConclusionThis case illustrates the challenge of diagnosing ACC, and that doublet immunotherapy with ipilimumab and nivolumab can have significant clinical efficacy in ACC.https://www.frontiersin.org/articles/10.3389/fonc.2023.1242560/fulladrenocortical canceradrenal cancerimmunotherapyipilimumabnivolumab |
| spellingShingle | Rebecca Charles Divine Madhu Alexander Powles Adam Boyde Owen Hughes Nagappan Kumar Sing Yu Moorcraft Case Report: Response to ipilimumab and nivolumab in a patient with adrenocortical carcinoma Frontiers in Oncology adrenocortical cancer adrenal cancer immunotherapy ipilimumab nivolumab |
| title | Case Report: Response to ipilimumab and nivolumab in a patient with adrenocortical carcinoma |
| title_full | Case Report: Response to ipilimumab and nivolumab in a patient with adrenocortical carcinoma |
| title_fullStr | Case Report: Response to ipilimumab and nivolumab in a patient with adrenocortical carcinoma |
| title_full_unstemmed | Case Report: Response to ipilimumab and nivolumab in a patient with adrenocortical carcinoma |
| title_short | Case Report: Response to ipilimumab and nivolumab in a patient with adrenocortical carcinoma |
| title_sort | case report response to ipilimumab and nivolumab in a patient with adrenocortical carcinoma |
| topic | adrenocortical cancer adrenal cancer immunotherapy ipilimumab nivolumab |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1242560/full |
| work_keys_str_mv | AT rebeccacharles casereportresponsetoipilimumabandnivolumabinapatientwithadrenocorticalcarcinoma AT divinemadhu casereportresponsetoipilimumabandnivolumabinapatientwithadrenocorticalcarcinoma AT alexanderpowles casereportresponsetoipilimumabandnivolumabinapatientwithadrenocorticalcarcinoma AT adamboyde casereportresponsetoipilimumabandnivolumabinapatientwithadrenocorticalcarcinoma AT owenhughes casereportresponsetoipilimumabandnivolumabinapatientwithadrenocorticalcarcinoma AT nagappankumar casereportresponsetoipilimumabandnivolumabinapatientwithadrenocorticalcarcinoma AT singyumoorcraft casereportresponsetoipilimumabandnivolumabinapatientwithadrenocorticalcarcinoma |